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OBJECTIVE — Type 2 diabetes is associated with increased cardiovascular risk. The role of
aggressiveglycemiccontrolinpreventingcardiovasculareventsisunclear.Anestedcase-control
study design was used to evaluate the association between average A1C and cardiovascular
outcomes.
RESEARCH DESIGN AND METHODS — Adults with type 2 diabetes were identiﬁed
amongmembersofKaiserPermanenteSouthernCalifornia.Type2diabeteswasidentiﬁedbased
onICD-9diagnosiscodesandeitherA1C7.5%orprescriptionsforhypoglycemicagents.Case
subjects were deﬁned based on nonfatal myocardial infarction, nonfatal stroke, or death attrib-
utedtocardiovasculareventsduringa3-yearwindow.Fourtype2diabetescontrolsubjectswere
matched to each case subject based on age, sex, and index date for the corresponding case. A
conditionallogisticregressionmodelwasusedtoestimatetheoddsratioofcardiovascularevents
and compare three patient groups based on average A1C measured in the preindex period (6,
6–8,8%).
RESULTS — Atotalof44,628controlsubjectswerematchedto11,157casesubjects.Patients
with an average A1C 6% were 20% more likely to experience a cardiovascular event than the
group with an average A1C of 6–8% (P  0.0001). Patients with an average A1C 8%
experienced a 16% increase in the likelihood of a cardiovascular event (P  0.0001). We found
evidence of statistical interaction with A1C category and LDL level (P  0.0002), use of cardio-
vascular medications (P  0.02), and use of antipsychotics (P  0.001).
CONCLUSIONS — High-risk patients with type 2 diabetes who achieved mean A1C levels
of 6% or failed to decrease their A1C to 8% are at increased risk for cardiovascular events.
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T
ype 2 diabetes is associated with an
increased risk of microvascular
complications, such as nephropa-
thy, neuropathy, and retinopathy, as well
as macrovascular complications includ-
ing myocardial infarction (MI) and
stroke. Diabetic patients who have not
hadapreviousMIhavethesameriskofan
infarction as nondiabetic patients who
have had a previous MI (1). Cardiovascu-
lar disease complications are the most
common cause of mortality in type 2 dia-
betic patients, accounting for 52% of
deaths in this population (2).
Tighter glycemic control and lower
A1C levels decrease the risk of microvas-
cular complications (3–6). The American
Diabetes Association recommends a tar-
get of A1C 7%, whereas the American
Association of Clinical Endocrinologists
recommends a A1C target of 6.5%
(7,8). Despite these established guide-
lines, questions remain regarding the
ideal A1C target for minimizing cardio-
vascular events in type 2 diabetes.
Observational studies (5,6,9–11)
have suggested a direct association be-
tween hyperglycemia and cardiovascular
events, whereas three large, randomized
clinical trials failed to establish a cardio-
vascular beneﬁt for intensive glycemic
control. The Veterans Affairs Diabetes
Trial (VADT) (10) randomly assigned di-
abetic subjects to intensive glycemic con-
trol (target A1C 6.0%) versus standard
treatment (target A1C 8–9%) and found
no signiﬁcant difference between the
treatment arms for major cardiovascular
events or all-cause mortality. Similarly,
the Action in Diabetes and Vascular Dis-
ease Trial (6) compared a target A1C of
6.5% with standard of care and found
nosigniﬁcantdifferenceinmacrovascular
events.Finally,theActiontoControlCar-
diovascular Risk in Diabetes (ACCORD)
Trial (11) compared a target A1C of
6.0%toatargetA1Cof7.0–7.9%inthe
standard arm. The trial was halted early
because of a signiﬁcant increase in all-
cause death and cardiovascular death in
the intensively treated arm.
We investigated whether the in-
creased risk associated with intensive gly-
cemic control found in the ACCORD trial
is observed in a managed-care popula-
tion. We deﬁne glycemic control as the
meanA1Clevelforeachpatientmeasured
over 3 years to mimic the average fol-
low-up period in the ACCORD study.
RESEARCH DESIGN AND
METHODS— We investigated the re-
lationship between glycemic control and
cardiovasculareventsusinganestedcase-
control design.
Study sample
DatawerederivedfromtheKaiserPerma-
nente Southern California (KPSC) Health
Plan, which contains information on pa-
tient demographics, diagnoses, prescrip-
tions, laboratory results, and medical and
hospital encounters. The KPSC member-
ship includes 3.3 million individuals,
representing 15% of the underlying pop-
ulation in southern California. Member-
ship is largely employer based (5% of
the KPSC population is Medicaid eligible
and 11% is Medicare eligible). The racial
composition is as follows: 42.9% non-
Hispanic white; 23.2% Hispanic white;
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0.2% American Indian/Alaskan; 9.4%
other; and 0.3% two or more races.
Adult patients (aged 18 years) with
type 2 diabetes were identiﬁed based on
two recorded type 2 diabetes diagnoses
between January 2002 and December
2007 and either an A1C 7.5% or a pre-
scription for oral hypoglycemic medica-
tion or insulin. Patients with a diagnosis
of polycystic ovarian syndrome, gesta-
tional diabetes, or serious illnesses in-
cluding HIV/AIDS, cancer, sickle cell
disease, cystic ﬁbrosis, organ transplant,
liverfailure,orrespiratoryfailurewereex-
cluded from the study.
Case subjects were deﬁned using a
primary composite end point of nonfatal
MI, nonfatal stroke, or death attributed to
cardiovascular causes (MI, stroke, heart
failure, or arrhythmia) between January
2005andDecember2007.Thedateofthe
case-deﬁningeventwaslistedastheindex
date. Control subjects without the pri-
mary end point during the time window
wereeligibleformatching.Eachcasesub-
ject was matched with four control sub-
jects based on age and sex. Control
subjects were assigned a pseudo–event
date equal to the index date of their
matched case subject. We excluded pa-
tientswithout3yearsofcontinuousKPSC
membership plus drug beneﬁts prior to
their index date, patients whose ﬁrst type
2 diabetes diagnosis occurred after their
indexdate,andpatientswithnorecorded
A1C in the observation window.
Case and control subjects were as-
signed to A1C categories based on their
average A1C measured over the 3 years
prior to their index date. Sensitivity
analyses were performed using their
median A1C and most recent A1C
prior to the index date. The study’s A1C
categories are consistent with the
ACCORD study (6, 6–8 [compari-
son group], and 8%).
A power analysis indicated that 672
case subjects, matched in a one-to-four
ratio to control subjects, would be neces-
sary to have 90% power to detect an odds
ratio of 1.15 between A1C categories,
adopting the two-sided 0.05 signiﬁcance
level (12).
Statistical analyses
We compared baseline characteristics be-
tween case and control subjects using the
two-sided t test for continuous variables
and the 
2 statistic for categorical vari-
ables. A conditional logistic regression
model was ﬁtted to estimate the odds
ratio of the primary end point in pa-
tients with A1C 6 and 8%, relative
to patients with A1C between 6 and
8%, adjusting for potential confound-
ers. We used a stratiﬁed model for sta-
tistically signiﬁcant interaction terms.
In a post hoc analysis, we ﬁtted a sepa-
rate model for patients on antipsychotic
medications. All analyses were per-
formed using SAS version 9.1.
Covariates
Weadjustedforanumberoflaboratory,
diagnostic, and prescription covariates
in the multivariate analysis. A dichoto-
mous variable was created to indicate if
the patient’s A1C was measured at least
sixtimesduringthe3-yearpreindexpe-
riod. Variability in preindex A1C values
was deﬁned as the difference between
the minimum and maximum A1C, with
an absolute difference of 1% considered
as clinically meaningful (5,10). Choles-
terol levels (LDL and HDL) measured in
the year prior to index date also were
included as covariates in the analyses.
Concurrent diabetes medications
were categorized into six commonly
prescribedregimenswithinKPSC:insu-
lin monotherapy; metformin mono-
therapy; sulfonylurea monotherapy;
insulinplusoralmedications;otheroral
medications or combinations; and no
diabetes medication. Medication adher-
ence with diabetic drugs was measured
using the proportion of days covered
over the year prior to index (13). Di-
chotomous variables also were deﬁned
to reﬂect the use of statins, ACE inhib-
itors, angiotensin receptor blockers
(ARBs), other antihypertensives, anti-
platelets, ﬁrst- and second-generation
antipsychotics, antiarrhythmics, tricy-
clic antidepressants, erythropoietin-
stimulating agents (ESAs), and -
agonists.
Dichotomous variables were created
toreﬂectcardiovasculareventsduringthe
3-year preindex period, including hospi-
talizations for MI, stroke, heart failure, or
arrhythmia. Outpatient cardiovascular
diagnosesincludedhypertension,periph-
eral vascular disease, or heart failure. Di-
agnoses of retinopathy, nephropathy,
chronic kidney disease, neuropathy, and
prior amputations suggesting microvas-
cular disease were included as covariates.
Finally, severe episodes of hypoglycemia
requiringemergency-departmentservices
or hospitalizations were captured using
dichotomous variables.
RESULTS
Study population
Apoolof254,118type2diabeticpatients
was identiﬁed, from which a total of
16,589 case subjects met the end point of
nonfatal MI, nonfatal stroke, or death at-
tributed to cardiovascular causes. After
matching and applying the exclusion cri-
teria, a total of 44,628 control subjects
were matched to 11,157 case subjects
(Fig. 1).
Demographic and clinical character-
istics for case and control subjects are
listed in Table 1. The mean age was
65.5  10.5 years, and 57% of the sub-
jectsweremale.Caseandcontrolsubjects
differed signiﬁcantly in all other charac-
teristics.Casesubjectsweretwiceaslikely
ascontrolsubjectstouseinsulinandwere
less likely to use statins, ACE inhibitors,
or ARBs. Case subjects were six times
more likely to use antipsychotics and
ESAs. Approximately 90% of the popula-
tion, of both case and control subjects,
had a cardiovascular diagnosis. Com-
pared with control subjects, case subjects
were four times more likely to have had a
cardiovascular event in 3-year preindex
period and approximately four times
more likely to have had a severe episode
of hypoglycemia. Case subjects also were
more likely to have preexisting microvas-
culardisease.Finally,thehighpercentage
of -agonist use reﬂects the high preva-
lence of asthma and chronic obstructive
pulmonary disease within the population
of both case and control subjects.
Primary analysis
In the unadjusted logistic model, patients
with a 3-year average A1C of 6% were
18% more likely to experience a cardio-
vascular event than patients with an aver-
age A1C of 6–8% (odds ratio 1.18
[95% CI 1.11–1.25]; P  0.0001). Pa-
tients with an average A1C of 8% were
31% more likely to have an event (1.31
[1.24–1.38]; P  0.0001) than the com-
parison group.
The results of the multivariate analy-
sis are presented in Table 2. Patients with
an average A1C of 6% were 20% more
likely to experience a cardiovascular
event, and patients with an average A1C
of 8% experienced a 16% increase in
likelihood of a cardiovascular event com-
pared with patients with an average A1C
between 6 and 8%, after adjusting for
potential confounders.
Compared with the group with no
diabetes medication use, patients using
A1C and cardiovascular outcomes
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rienced a 2.5-fold increase in the risk of a
cardiovascular event, whereas patients
treated with sulfonylurea monotherapy
and other combinations of oral medica-
tions experienced an increased risk of
55%. Metformin monotherapy was not
associated with an excess cardiovascular
risk. Adherence to diabetes medications
conferred a signiﬁcant protective effect,
with each 10% increase in proportion of
dayscoveredbeingassociatedwitha44%
decrease in the risk of a cardiovascular
event.
Statins, ACE inhibitors, and ARBs
were associated with a decrease in odds,
whereas antipsychotics, ESAs and tricy-
clic antidepressants were associated with
anincreasedriskofcardiovascularevents.
Complicationssuchasprioramputations,
severe hypoglycemia, and history of pre-
vious cardiovascular events were signiﬁ-
cantly associated with cardiovascular
events, as were indicators of microvascu-
lar disease (including nephropathy, neu-
ropathy, and retinopathy). High LDL
(100 mg/dl) also was signiﬁcantly
associated with cardiovascular events,
whereas high HDL (40 mg/dl) was
protective.
The stratiﬁed analysis evaluating the
impact of A1C categories on cardiovascu-
lar outcomes within selected populations
Figure 1—Selection of study population.
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groups, an average A1C of 8% was as-
sociated with an increased risk of
cardiovascular events; however, for those
with high LDL or those taking cardiovas-
cular medications other than ACE inhib-
itors and ARBs, an A1C 6% was not
signiﬁcantly associated with event risk.
TheﬁnaltwogroupsinTable3reﬂect
that 2,539 patients taking antipsychotics
had a different risk proﬁle from those not
taking antipsychotics. For patients taking
antipsychotics, an A1C 8% was associ-
ated with a threefold-increased odds of
cardiovascularevents,whereasA1C6%
was not signiﬁcantly associated with car-
diovascular events. For those not taking
antipsychotics, the risk proﬁle resembled
that of the overall study, with both A1C
categoriesshowingstatisticallysigniﬁcant
increases in cardiovascular risk relative to
the 6–8% group.
Sensitivity analysis
Our model was robust to changes in the
deﬁnition of glycemic control. Deﬁning
glycemic categories based on the median
A1C yielded similar results in which the
risk of cardiovascular events in patients
with median A1C 6% was 21% higher
than for patients with a A1C between 6
and 8%. Patients with median A1C 8%
were at 10% increased risk of cardiovas-
cular events. Using the most recent A1C
prior to index, patients with A1C 6%
were 41% more likely to have an event
thanthoseneartarget,whereasthosewith
A1C 8% were at a 5% increased odds of
a cardiovascular event.
CONCLUSIONS — In this study, pa-
tients with type 2 diabetes who achieved
mean A1C levels of 6% or who failed to
decrease their A1C to 8% over a 3-year
period were at increased risk for cardio-
vascular events compared with patients
with mean A1C levels between 6 and
8%. Although treatment effects varied
across subgroups with different risk pro-
ﬁles, these subgroup analyses are consis-
tent with the core results.
These results are consistent with the
ACCORD trial, which found a signiﬁcant
increase in all-cause death and cardiovas-
cular death in the intensively treated arm
(11). Our study also lends support to the
results of a recent retrospective cohort
study by Currie et al. (14), which found a
U-shaped association between survival
and A1C. In this study, patients with the
lowest A1C levels (median 6.4%) were at
a52%increasedriskofall-causemortality
Table 1—Patient characteristics
Variable
Case
subjects
Control
subjects P
n 11,157 44,628
Mean age (years) 65.5  10.5 65.5  10.5 Matching
variable
Male sex 6,359 (57) 25,436 (57) Matching
variable
Mean A1C level (%)
6 1,580 (14.2) 5,801 (13.0) 0.001
6–8 6,818 (61.1) 29,564 (66.3) 0.001
8 2,759 (24.7) 9,263 (20.8) 0.001
Measured 6 A1Cs over 3-year follow-up 6,055 (54.3) 22,150 (49.6) 0.001
A1C range 1.0% 8,186 (73.4) 29,251 (65.5) 0.001
Diabetes medications
Insulin only 2,102 (18.8) 3,386 (7.6) 0.001
Metformin only 681 (6.1) 5,908 (13.2) 0.001
Sulfonylurea only 2,230 (20.0) 10,142 (22.7) 0.001
Insulin and oral medications 2,579 (23.1) 5,747 (12.9) 0.001
Other oral medications/oral combination 2,444 (21.9) 14,413 (32.3) 0.001
No diabetes medications 1,121 (10.1) 5,032 (11.3) 0.001
Mean proportion of days covered of
diabetes medications
0.69  0.35 0.71  0.35 0.001
Other medications
Statins 7,787 (69.8) 33,602 (75.3) 0.001
ACE inhibitors/ARBs 8,624 (77.3) 35,731 (80.1) 0.001
Other antihypertensives/antiplatelets 4,241 (38.0) 11,195 (25.1) 0.001
Antipsychotics 1,822 (16.3) 1,102 (2.5) 0.001
Antiarrhythmics 423 (3.8) 510 (1.1) 0.001
Tricyclic antidepressant 505 (4.5) 468 (1.1) 0.001
ESAs 1,385 (12.4) 911 (2.0) 0.001
-Agonists 2,292 (20.5) 4,905 (11.0) 0.001
Prior cardiovascular event 2,604 (23.3) 2,601 (5.8) 0.001
MI only 293 (11.3) 428 (16.5)
Stroke only 224 (8.6) 289 (11.1)
Heart failure only 1,436 (55.1) 899 (34.6)
Arrhythmia only 491 (18.9) 911 (35.0)
MI and stroke 7 (0.3) 5 (0.2)
MI and heart failure 60 (2.3) 24 (0.9)
MI and arrhythmia 15 (0.6) 22 (0.8)
Stroke and heart failure 6 (0.2) 2 (0.1)
Stroke and arrhythmia 6 (0.2) 2 (0.1)
Heart failure and arrhythmia 66 (2.5) 19 (0.7)
Cardiovascular diagnosis 10,297 (92.3) 38,761 (86.9) 0.001
Hypertension only 5,342 (51.9) 30,495 (78.7)
Peripheral vascular disease only 88 (0.8) 235 (0.6)
Heart failure only 123 (1.3) 144 (0.3)
Peripheral vascular disease and heart
failure
34 (0.3) 26 (0.1)
Hypertension and heart failure 1,861 (18.1) 3,025 (7.8)
Hypertension and peripheral vascular
disease
1,423 (13.8) 3,590 (9.3)
Hypertension, peripheral vascular disease,
and heart failure
1,426 (13.8) 1,246 (3.2)
LDL 100 mg/dl 3,499 (31.4) 15,465 (34.7) 0.001
LDL 100 mg/dl 6,478 (58.0) 25,768 (57.7)
Missing LDL 1,180 (10.6) 3,395 (7.6)
HDL 40 mg/dl 5,278 (47.3) 27,409 (61.4) 0.001
(continued)
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7.5%. In addition, patients in the highest
A1C group (median A1C 10.5%) were at
79%increasedrelativerisk.However,our
resultsdifferfromthatoftheUKProspec-
tive Diabetes Study (UKPDS) 10-year fol-
low-up, which demonstrated that
intensive treatment was associated with a
15%relativeriskreductioninMI(relative
risk 0.85 [95% CI 0.74–0.97]; P  0.01)
(5).
The characteristics of our patient
population are comparable with the
ACCORD trial and the study by Currie et
al.(14)intermsofageandcardiovascular
risk proﬁle and less comparable with the
UKPDS.Ourstudysamplewascomposed
of mostly elderly subjects (mean age 65.5
years), whereas the UKPDS recruited
younger,newlydiagnosedpatients(mean
age 53 years), with 8% of the popula-
tion having a history of cardiovascular
disease. By contrast, 90% of our study
population had comorbid hypertension
and 60% had microvascular disease.
The ACCORD trial also included patients
with previous cardiovascular events or
multiple cardiovascular risk factors. The
study by Currie et al. included patients
with a history of medication escalation,
and63%ofthepopulationhadasmoking
history. These results suggest that in el-
derly patients with a high cardiovascular
risk proﬁle, intensive glycemic control
should be initiated with caution.
The medication regimens used in the
different studies also warrant discussion.
In our study, metformin monotherapy
was not associated with excess cardiovas-
cular risk, whereas other combinations of
oral drugs, including sulfonylureas, ex-
hibited an increased risk of events. Simi-
larly, in the UKPDS, the relative risk
reductions for death and MI were greater
for patients receiving metformin-based
regimens than for those on sulfonylurea-
based regimens. In our study, insulin use
alone or in combination with oral medi-
cations was associated with a 2.5-fold–
increased risk of cardiovascular events.
These ﬁndings are consistent with Currie
et al. (15), which identiﬁed a lower sur-
vival rate in insulin users compared with
oralmedicationusers.Themechanismfor
theexcessriskassociatedwithinsulinand
sulfonylurea use is not clearly under-
stood; however, it is possible that hypo-
glycemia plays a role. It has been
proposed that hypoglycemia may precip-
itate cardiac arrhythmias through hypo-
kalemia and sympatho-adrenal activation
(15,16). In addition, glucose variability
has been implicated as a factor in oxida-
tive stress and vascular inﬂammation
(17).Alternatively,insulinusemayreﬂect
more advanced disease.
Taking antipsychotics also appeared
to confer an increased risk of cardiovas-
cular events, primarily driven by the use
of ﬁrst-generation antipsychotics, which
Table 1—Continued
Variable
Case
subjects
Control
subjects P
HDL 40 mg/dl 4,669 (41.8) 13,760 (30.8)
Missing HDL 1,210 (10.8) 3,459 (7.8)
Retinopathy 3,886 (34.8) 10,062 (22.6) 0.001
Nephropathy 8,005 (71.8) 23,194 (52.0) 0.001
Neuropathy 4,487(40.2) 12,016 (26.9) 0.001
Prior amputations 466 (4.2) 274 (0.6) 0.001
Prior severe hypoglycemia 447 (4.0) 520 (1.2) 0.001
Data are n (%) or means  SD. Prior cardiovascular event  hospitalization for MI, stroke, heart failure, or
arrhythmia in the 3-year preindex period. Cardiovascular diagnosis  hypertension, heart failure, and/or
peripheral vascular disease. Prior severe hypoglycemia  emergency-room visit or hospitalization with a
primary diagnosis of hypoglycemia.
Table 2—Conditional logistic regression model of cardiovascular events
Covariate Odds ratio (95% CI) P
Mean A1C level (%)
6.0 1.20* (1.10–1.31) 0.001
6.0–8.0 Reference —
8.0 1.16* (1.09–1.25) 0.001
6 A1C tests over prior 3 years 0.84 (0.80–0.89) 0.001
A1C range 1.0% 1.29 (1.21–1.38) 0.001
Diabetes medications
Insulin only 2.65 (2.31–3.05) 0.001
Metformin only 1.06 (0.92–1.23) 0.41
Sulfonylurea only 1.55 (1.36–1.76) 0.001
Insulin and oral medications 2.56 (2.19–3.00) 0.001
Other oral medications/oral combination 1.55 (1.33–1.80) 0.001
No diabetes medications Reference —
Mean proportion of days covered of
diabetes medications
0.56 (0.49–0.63) 0.001
Statins 0.75 (0.70–0.80) 0.001
ACE inhibitors/ARBs 0.80 (0.74–0.86) 0.001
Other antihypertensives/antiplatelets 1.34 (1.25–1.43) 0.001
Antipsychotics 7.10 (6.24–8.09) 0.001
Antiarrhythmics 1.54 (1.30–1.83) 0.001
Tricyclic antidepressant 2.91 (2.44–3.46) 0.001
ESAs 2.75 (2.46–3.08) 0.001
-Agonists 1.63 (1.52–1.75) 0.001
Prior cardiovascular event 3.10 (2.87–3.36) 0.0001
Cardiovascular diagnosis 1.41 (1.28–1.56) 0.0001
LDL 100 mg/dl 1.14 (1.06–1.22) 0.0033
HDL  40 mg/dl 0.67 (0.63–0.71) 0.0001
Retinopathy 1.13 (1.07–1.21) 0.0001
Nephropathy 1.68 (1.58–1.79) 0.0001
Neuropathy 1.19 (1.12–1.26) 0.0001
Prior amputations 3.28 (2.52–4.26) 0.0001
Prior severe hypoglycemia 1.67 (1.40–1.99) 0.0001
*Odds ratio estimated using multivariate analysis controlling for all covariates listed in table. Prior cardio-
vascular event  hospitalization for MI, stroke, heart failure, arrhythmia in the 3-year preindex period.
Cardiovascular diagnosis  hypertension, heart failure, and/or peripheral vascular disease. Prior severe
hypoglycemia  emergency-room visit or hospitalization with primary diagnosis of hypoglycemia.
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bances and QTc prolongation (18). To a
lesser extent, second-generation antipsy-
chotics, which are associated with weight
gain and metabolic disturbances, also
contributed to this effect (19). As ex-
pected,ourdatashowthatpatientstaking
antipsychotics differed signiﬁcantly in all
clinicalcharacteristicsfromthosenottak-
ing antipsychotics; thus, it is likely that
thetwosubgroupshavedifferentriskpro-
ﬁles. The secondary analysis revealed that
intensiveglycemiccontrolinpatientstak-
ing antipsychotics was associated with
cardiovascular events to a lesser extent
thaninpatientsnottakingantipsychotics.
The effect of antipsychotics on cardiovas-
cular risk in diabetic patients deserves
further investigation.
Our study is subject to a number of
limitations. First, the preindex time win-
dow was limited to 3 years. It is possible
that any cardiovascular beneﬁts of inten-
sive glycemic control may take longer to
become apparent, as shown in UKPDS.
However, even short-term cardiovascular
risk associated with average A1C levels
6% is a signiﬁcant ﬁnding with clinical
implications. Second, the use of condi-
tional logistic regression in our analysis
resulted in odds ratios that may overesti-
mate relative risk when the absolute rate
of events is high (20). Although the mag-
nitude of risk may be overestimated, the
direction of risk associated with intensive
glycemic control is valid. Third, the non-
randomized design may subject the re-
sultstotreatmentselectionbias;however,
the completeness of the KPSC database
allowed us to control for multiple poten-
tial confounders, including laboratory re-
sults and hospitalization data. Still, some
key demographic data were missing, in-
cluding race and socioeconomic status.
Additionally, BMI data were not available
for 66% of the study population and
smokingstatusdatagenerallyaremissing.
Finally, duration of diabetes was not
available, which was an important deter-
minant of risk associated with intensive
treatment based on post hoc analyses of
VADT (21).
Ourﬁndingssuggestthatwithrespect
to A1C control, aggressive lowering may
not be appropriate for all type 2 diabetic
patients. Although the potential for selec-
tion bias precludes us from drawing
causal conclusions about the relationship
between mean A1C and cardiovascular
risk, our ﬁndings, together with those of
the ACCORD trial and the study by Cur-
rie et al., have implications for clinical
practice.Whereasuncontrolledhypergly-
cemia is an established risk factor for mi-
crovascular and macrovascular disease,
intensiveA1Ccontrolmaynotbethebest
approach for all type 2 diabetic patients.
Initiation of intensive glycemic control
warrants careful consideration of individ-
ual cardiovascular risk proﬁles. For a
given individual, aggressive treatment
strategies should carefully weigh the ben-
eﬁts of preventing microvascular compli-
cations with the risk of precipitating
cardiovascular events. Further research is
neededtoidentifythetypesofpatientsfor
whom intensive glycemic control would
be most appropriate, as well as selection
ofappropriatemedicationregimens.Ulti-
mately, mitigating cardiovascular risk
requires a multifactorial approach, glyce-
mic control coupled with lipid lowering
andbloodpressurecontrol,aswellaslife-
style interventions (22).
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